{"id":36099,"date":"2023-08-22T13:40:43","date_gmt":"2023-08-22T11:40:43","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/"},"modified":"2024-08-09T07:37:55","modified_gmt":"2024-08-09T05:37:55","slug":"ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/","title":{"rendered":"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3"},"content":{"rendered":"<ul>\n<li style=\"margin-bottom:3px\">Ipsen obtient une licence exclusive pour d\u00e9velopper, fabriquer et commercialiser un programme d\u2019inhibiteur de la METTL3 en phase pr\u00e9-clinique.<\/li>\n<li style=\"margin-bottom:3px\">Cette collaboration avec Accent Therapeutics compl\u00e8te les partenariats annonc\u00e9s derni\u00e8rement et soutient la strat\u00e9gie d\u2019expansion d\u2019Ipsen dans les h\u00e9mopathies malignes, avec un accent particulier sur la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb.<\/li>\n<\/ul>\n<p><b>Paris (France), le 18 octobre 2021 \u2013\u00a0<\/b>Ipsen (Euronext\u00a0: IPN\u00a0; ADR\u00a0: IPSEY) et Accent Therapeutics ont sign\u00e9 un accord exclusif de collaboration mondiale pour la recherche, le d\u00e9veloppement, la fabrication et la commercialisation du programme METTL3 d\u2019Accent.<br \/>La leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb (LMA) est un cancer du sang et de la moelle osseuse difficile \u00e0 traiter. Elle repr\u00e9sente un tiers des nouveaux cas de leuc\u00e9mie aux \u00c9tats-Unis chaque ann\u00e9e.1\u00a0\u00c0 l\u2019\u00e9chelle mondiale, la pr\u00e9valence de la LMA n\u2019a cess\u00e9 d\u2019augmenter d\u2019ann\u00e9e en ann\u00e9e depuis deux d\u00e9cennies.2\u00a0Les prot\u00e9ines modificatrices d\u2019ARN (en anglais\u00a0<em>RNA modifying proteins<\/em>, RMP) sont une classe de prot\u00e9ines qui contr\u00f4lent la biologie de l\u2019ARN sous plusieurs aspects et repr\u00e9sentent une nouvelle approche cibl\u00e9e pour le traitement potentiel de divers cancers. L\u2019enzyme METTL3 est une RMP qui a \u00e9t\u00e9 valid\u00e9e en phase pr\u00e9-clinique en tant que nouvelle cible th\u00e9rapeutique pour traiter la LMA1,3. Cette collaboration allie l\u2019expertise d\u2019Accent Therapeutics dans les th\u00e9rapies ciblant les RMP avec les comp\u00e9tences et l\u2019exp\u00e9rience solides d\u2019Ipsen dans le d\u00e9veloppement et la commercialisation de m\u00e9dicaments en oncologie. Ipsen figure parmi les 14 soci\u00e9t\u00e9s biopharmaceutiques les plus importantes au monde en oncologie.<\/p>\n<p>Christelle Huguet, Vice Pr\u00e9sidente Senior, Head of Research, External Innovation &amp; Early Development chez Ipsen, a d\u00e9clar\u00e9\u00a0:\u00a0<em>\u00ab\u00a0L\u2019oncologie reste une orientation cl\u00e9 pour Ipsen dans le d\u00e9veloppement de notre portefeuille de produits en R&amp;D. Nous sommes ravis de nous associer \u00e0 Accent Therapeutics pour faire progresser le programme METTL3 et ainsi \u00e9tendre notre pr\u00e9sence en oncologie h\u00e9matologique. Nos \u00e9quipes sont fermement engag\u00e9es \u00e0 apporter des solutions l\u00e0 o\u00f9 les besoins m\u00e9dicaux non satisfaits restent \u00e9lev\u00e9s, y compris dans les cancers rares. Cette nouvelle collaboration avec Accent incarne pleinement la mission et la strat\u00e9gie de croissance d\u2019Ipsen.\u00a0\u00bb<\/em><\/p>\n<p>Shakti Narayan, PDG d\u2019Accent Therapeutics, a d\u00e9clar\u00e9 : \u00ab\u00a0<em>Cette collaboration allie l\u2019engagement d\u2019Ipsen \u00e0 d\u00e9velopper et commercialiser des m\u00e9dicaments innovants en oncologie avec l\u2019expertise de pointe d\u2019Accent dans la modification d\u2019ARN.<\/em>\u00a0<em>Accent Therapeutics est r\u00e9solu \u00e0 d\u00e9velopper son riche portefeuille de nouvelles th\u00e9rapies ciblant la RMP et nous sommes tr\u00e8s heureux de confier notre programme METTL3 \u00e0 l\u2019\u00e9quipe innovante d\u2019Ipsen pour apporter ce nouveau traitement exp\u00e9rimental aux patients qui en ont besoin.\u00a0<\/em>\u00bb<\/p>\n<p>Selon les termes de l\u2019accord, Ipsen versera \u00e0 Accent Therapeutics jusqu\u2019\u00e0 446 millions de dollars dont des paiements li\u00e9s \u00e0 l\u2019atteinte de certaines \u00e9tapes pr\u00e9-cliniques, cliniques, r\u00e9glementaires et commerciales, ainsi que des redevances progressives sur les ventes nettes (\u00e0 un taux compris entre un pourcentage initial inf\u00e9rieur \u00e0 10% et un pourcentage maximum l\u00e9g\u00e8rement sup\u00e9rieur \u00e0 10%).<\/p>\n<p>\u00a0\u00a0 <\/p>\n<ol>\n<li style=\"margin-bottom:3px\">American Cancer Society. Key statistics for Acute Myeloid Leukemia.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8deMH7BwNOZ_3SohixAcWWol54-gNTGN43eKrS13JQtviJr-pu1_Lj93dBtBIu70tT_Ubd5MWFM7bcEKGf0YyarRDnosNc7Ml5joafZb0yavQ64CCcamkHTFLgEevG9BDlrvs_JPT2jzvQVgRhE9wVG0XcGTUho0btPd8b291_8NsbRs5Mac7B4YLxLJF8A5tOAAWitPMTbFQ3s7AZmFhLQDQ7T2qrCZfBwiKI8DN8PY02XI8HCA9dGfHECaDVL7\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html<\/b><\/a><\/li>\n<li style=\"margin-bottom:3px\">Yin Dong, Oumin Shi, Quanxiang Zeng, Xiaoquin Lu, Wei Wang, Yong Li, Qi Wang, Yong Li and Qi Wang, Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Experimental Hematology &amp; Oncology 9, Article number 14. 2020<\/li>\n<li style=\"margin-bottom:3px\">Shane M Buker, Zachary A Gurard-Levin, Benjamin D Wheeler, Michael D Scholle, April W Case, Jeffrey L Hirsch, Scott Ribich, Robert A Copeland, P Ann Boriack-Sjodin. A Mass Spectrometric Assay of METTL3\/METTL14 Methyltransferase Activity. SLAS Discov. 2020 Apr;25(4):361-371. Epub 2019 Oct 4.<\/li>\n<\/ol>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Pi\u00e8ce jointe<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=JyHvTFzV7iIs6IRFwC8rwjnKozn9Elmys9KzAwsrvij4Yu4BgTHz1cgOV8XBSPDc6XdFVmOFQNyD8Xo_ZSyqvzzpx4e5vLeaFTuUiP6KOj2nsz1sbXn2_M_isLGPRuHo-SHb9HO4AnnuLs6kJrW8D2NvMAp2vZwmtNhwwh_Xy2u5xz3xw_oDTbbXX-vaYnrjtPMwpJ59ZlzG_f7f4ldhzg==\" title=\"Ipsen-Collaboration-Accent-18-Octobre-2021\" rel=\"nofollow noopener\">Ipsen-Collaboration-Accent-18-Octobre-2021<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556,3560],"tags":[],"class_list":["post-36099","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","category-oncology-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-09T05:37:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3\",\"datePublished\":\"2023-08-22T11:40:43+00:00\",\"dateModified\":\"2024-08-09T05:37:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/\"},\"wordCount\":666,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\",\"Oncologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/\",\"name\":\"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2023-08-22T11:40:43+00:00\",\"dateModified\":\"2024-08-09T05:37:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/","og_site_name":"Global","article_modified_time":"2024-08-09T05:37:55+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3","datePublished":"2023-08-22T11:40:43+00:00","dateModified":"2024-08-09T05:37:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/"},"wordCount":666,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate","Oncologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/","name":"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2023-08-22T11:40:43+00:00","dateModified":"2024-08-09T05:37:55+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-integre-un-nouveau-programme-a-son-portefeuille-rd-de-produits-doncologie-en-phase-pre-clinique-grace-a-une-collaboration-mondiale-exclusive-avec-accent-therapeutics-ciblant-la-pr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen int\u00e8gre un nouveau programme \u00e0 son portefeuille R&amp;D de produits d\u2019oncologie en phase pr\u00e9-clinique gr\u00e2ce \u00e0 une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la prot\u00e9ine modificatrice d\u2019ARN METTL3"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36099"}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36099\/revisions"}],"predecessor-version":[{"id":63613,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36099\/revisions\/63613"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}